Ignite Proteomics
About Ignite Proteomics
Ignite Proteomics is a Healthcare company founded in 2024, and was acquired by Aditx Therapeutics in March 2026. It offers proteomics assays for physician support and therapeutic development. It operates on a B2B model. Ignite Proteomics offers products and services including 32-analyte Assay, Reverse Phase Protein Array, and Laser Capture Microdissection. Its focus areas include Biotech, Proteomics, Assay Services and Oncology Research.
Company details
Ignite Proteomics specializes in proteomics through a 32-analyte assay that aids physicians in data-driven treatment decisions for oncology. It supports BioPharma partners by using techniques like Reverse Phase Protein Array and laser capture microdissection for therapeutic development. The company focuses on predictive protein biomarkers and collaborates with healthcare professionals.
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website igniteproteomics.com
- Social LinkedIn
- Acquired by Aditx Therapeutics (Mar 2026)
- Investors
- Acquired byAditx Therapeutics
(Mar 2026)
Products & Services of Ignite Proteomics
Ignite Proteomics offers a comprehensive portfolio of products and services, including 32-analyte Assay, Reverse Phase Protein Array, and Laser Capture Microdissection.
Assists physicians with data-driven treatment decisions using protein biomarkers.
Enables proteome assessment for oncology therapeutic development.
Supports targeted proteome analysis in clinical trials.
Investors in Ignite Proteomics
Ignite Proteomics has secured backing from 1 investor. Prominent investors backing the company include Aditx Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Immune monitoring solutions are provided to the medical community. | 2017 | aditxt.com | Loma Linda, United States |
Investor details for Ignite Proteomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ignite Proteomics
2 dated milestones of Ignite Proteomics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Ignite Proteomics is founded.
- Exit Acquired by Aditx Therapeutics.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ignite Proteomics
Complete news archive for Ignite Proteomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ignite Proteomics
Ignite Proteomics was founded in 2024.
Ignite Proteomics specializes in proteomics through a 32-analyte assay that aids physicians in data-driven treatment decisions for oncology. It supports BioPharma partners by using techniques like Reverse Phase Protein Array and laser capture microdissection for therapeutic development. The company focuses on predictive protein biomarkers and collaborates with healthcare professionals.
Ignite Proteomics offers 32-analyte Assay, Reverse Phase Protein Array, and Laser Capture Microdissection.
Ignite Proteomics has 1 investor. Key investors include Aditx Therapeutics.
Yes. Ignite Proteomics was acquired by Aditx Therapeutics in March 2026.